Notch1:DLL4 [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit
The Notch1:DLL4 [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit is designed for screening and profiling molecules that block the binding of Notch1 (neurogenic locus notch homolog protein 1) and DLL4 (delta like canonical notch ligand 4). This kit comes in a convenient 96-well format, with enough recombinant purified Notch1, biotin-labeled DLL4, streptavidin-labeled HRP, and assay buffer for 100 binding reactions. The key to this kit is the high sensitivity of detection of biotin-labeled DLL4 by streptavidin-HRP.
Figure 1: Illustration of the mechanism of Notch1:DLL4 [Biotinylated] Inhibitor Screening Chemiluminescence Assay Kit.
Notch1 is coated onto a 96-well plate. After blocking, the plate is pre-incubated with an inhibitor or neutralizing antibody. After incubation with Biotin-DLL4, the plate is washed and Streptavidin-HRP is added. After the ELISA ECL substrate is added the resulting signal can be measured using a chemiluminescence microplate reader. The chemiluminescence signal is proportional to the binding of Notch1 to DLL4.
- 1x PBS buffer (Phosphate Buffer Saline)
- Microplate reader capable of reading chemiluminescence
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform
| Catalog # | Name | Amount | Storage |
| 101904 | Human DLL4, Fc-Avi-Tag, Biotin-Labeled * | 10 µg | -80°C |
| 101897 | Human Notch1, Avi-His-Tag* | 10 µg | -80°C |
| 79311 | 3x Immuno Buffer 1 | 50 ml | -20°C |
| 79728 | Blocking Buffer 2 | 50 ml | +4°C |
| 79742 | Streptavidin-HRP | 10 µl | +4°C |
| 79670 | ELISA ECL Substrates A (translucent bottle) | 6 ml | Room Temp |
| ELISA ECL Substrates B (brown bottle) | 6 ml | Room Temp | |
| 79699 | White 96-well microplate | 1 | Room Temp |
*The initial concentration of both DLL4 and Notch1 is lot-specific and will be indicated on the tube containing the protein.
The Notch (neurogenic locus notch homolog protein) signaling is evolutionally highly conserved and implicated in various aspects of cancer development and progression. Aberrant activation of Notch1 signaling, often through mutations or overexpression, is associated with several types of cancer, including leukemia, breast cancer, lung cancer, and others. DLL4 (delta like canonical notch ligand 4), as a ligand of Notch receptors, can also influence tumor angiogenesis, promoting the growth of blood vessels within tumors and facilitating tumor progression. As Notch1 and DLL4 signaling pathway plays significant roles in cancer development, several Notch1 and DLL4 neutralizing antibodies have been evaluated in preclinical studies and clinical trials across various cancer types.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.